文献速递血栓与止血

糖皮质激素治疗新诊断免疫性血小板减少症使中间型单核细胞由促炎转为抗炎表型

Glucocorticoid treatment in patients with newly diagnosed immune thrombocytopenia switches CD14++ CD16+ intermediate monocytes from a pro-inflammatory to an anti-inflammatory phenotype.
PubMed 文献 · Br J Haematol · 2020-12-18

研究采用多参数流式细胞术分析新诊断未治疗ITP患者单核细胞表型,发现中间型单核细胞(CD14++CD16+)扩增且呈促炎表型。泼尼松龙治疗2周后该亚群比例下降并表达抗炎标志物,提示单核细胞参与ITP发病及激素治疗反应。

要点

  • 新诊断未治疗ITP患者中间型单核细胞扩增且呈促炎表型。
  • 泼尼松龙1 mg/kg每日治疗2周后中间型单核细胞比例下降并转为抗炎表型。
  • 慢性ITP接受TPO受体激动剂者未见此激素诱导的表型变化。

核心结论

  • 单核细胞可能参与ITP发病机制及对糖皮质激素治疗的临床反应。

研究设计与样本

  • 采用多参数流式细胞术分析新诊断未治疗ITP患者、健康对照及治疗后患者的单核细胞表型。

主要发现

  • 新诊断未治疗ITP患者中间型单核细胞(CD14++CD16+)扩增,高表达CD64和CD80。
  • 泼尼松龙1 mg/kg每日治疗2周后中间型单核细胞比例下降,CD206和CD163表达增强。
  • 健康对照单核细胞与新诊断ITP患者治疗前后单核细胞表型明显不同。
  • 慢性ITP接受血小板生成素受体激动剂者未观察到糖皮质激素诱导的表型。

临床怎么用

  • 糖皮质激素治疗新诊断ITP可促使中间型单核细胞由促炎向抗炎表型转化,支持单核细胞作为疗效监测的潜在标志。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is thought to result from an aberrant adaptive autoimmune response, involving autoantibodies, B and T lymphocytes, directed at platelets and megakaryocytes. Previous reports have demonstrated skewed CD4+ T-helper subset distribution and enhanced production of pro-inflammatory cytokines such as interleukin 17A and interferon gamma. The role of monocytes (MCs) in ITP is less widely described, but innate immune cells have a role in shaping CD4+ T-cell phenotypes. Glucocorticoids (GCs) are commonly used for first-line ITP treatment and modulate a broad range of immune cells including T cells and MCs. Using multiparameter flow cytometry analysis, we demonstrate the expansion of intermediate MCs (CD14++ CD16+ ) in untreated patients with newly diagnosed ITP, with these cells displaying a pro-inflammatory phenotype, characterised by enhanced expression of CD64 and CD80. After 2 weeks of prednisolone treatment (1 mg/kg daily), the proportion of intermediate MCs reduced, with enhanced expression of the anti-inflammatory markers CD206 and CD163. Healthy control MCs were distinctly different than MCs from patients with ITP before and after GC treatment. Furthermore, the GC-induced phenotype was not observed in patients with chronic ITP receiving thrombopoietin receptor agonists. These data suggest a role of MCs in ITP pathogenesis and clinical response to GC therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Williams EL, Stimpson ML, Lait PJP, et al. Glucocorticoid treatment in patients with newly diagnosed immune thrombocytopenia switches CD14++ CD16+ intermediate monocytes from a pro-inflammatory to an anti-inflammatory phenotype. Br J Haematol. 2020. PMID: 33338291. doi:10.1111/bjh.17205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。